Novartis (NVS) Competitors

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Johnson & Johnson has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Novartis has a net margin of 23.29% compared to Johnson & Johnson's net margin of 21.48%. Novartis' return on equity of 38.56% beat Johnson & Johnson's return on equity.

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

In the previous week, Johnson & Johnson had 49 more articles in the media than Novartis. MarketBeat recorded 90 mentions for Johnson & Johnson and 41 mentions for Novartis. Johnson & Johnson's average media sentiment score of 1.26 beat Novartis' score of -0.54 indicating that Johnson & Johnson is being referred to more favorably in the media.

Johnson & Johnson currently has a consensus target price of $274.13, indicating a potential upside of 3.09%. Novartis has a consensus target price of $153.00, indicating a potential upside of 11.50%. Given Novartis' higher probable upside, analysts clearly believe Novartis is more favorable than Johnson & Johnson.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Merck & Co., Inc. had 8 more articles in the media than Novartis. MarketBeat recorded 49 mentions for Merck & Co., Inc. and 41 mentions for Novartis. Merck & Co., Inc.'s average media sentiment score of 1.05 beat Novartis' score of -0.54 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Novartis presently has a consensus target price of $153.00, indicating a potential upside of 11.50%. Merck & Co., Inc. has a consensus target price of $151.32, indicating a potential upside of 5.07%. Given Novartis' higher possible upside, research analysts clearly believe Novartis is more favorable than Merck & Co., Inc..

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.4%. Novartis pays out 46.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novartis has a net margin of 23.29% compared to Merck & Co., Inc.'s net margin of 4.77%. Novartis' return on equity of 38.56% beat Merck & Co., Inc.'s return on equity.

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Merck & Co., Inc. has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

13.1% of Novartis shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Astrazeneca has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has a net margin of 23.29% compared to Astrazeneca's net margin of 17.02%. Novartis' return on equity of 38.56% beat Astrazeneca's return on equity.

Novartis has lower revenue, but higher earnings than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 29.19%. Novartis has a consensus price target of $153.00, suggesting a potential upside of 11.50%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities analysts plainly believe Astrazeneca is more favorable than Novartis.

In the previous week, Novartis had 16 more articles in the media than Astrazeneca. MarketBeat recorded 41 mentions for Novartis and 25 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.60 beat Novartis' score of -0.54 indicating that Astrazeneca is being referred to more favorably in the media.

Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 1.9%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Novo Nordisk A/S pays out 19.8% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Novo Nordisk A/S had 3 more articles in the media than Novartis. MarketBeat recorded 44 mentions for Novo Nordisk A/S and 41 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.48 beat Novartis' score of -0.54 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Novo Nordisk A/S has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Novo Nordisk A/S currently has a consensus price target of $64.94, indicating a potential upside of 50.90%. Novartis has a consensus price target of $153.00, indicating a potential upside of 11.50%. Given Novo Nordisk A/S's higher possible upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity.